Tuberous sclerosis complex (TSC) is an autosomal dominant neurogenetic disorder affecting about 1 in 6000 people and is caused by mutations in either TSC1 or TSC2. This disorder is characterized by increased activity of mammalian target of rapamycin complex 1 (mTORC1), which is involved in regulating ribosomal biogenesis and translation initiation. We measured the effects of Tsc2 haploinsufficiency (Tsc2 method. This quantitative autoradiographic method includes an estimate of the integrated specific activity of the tracer amino acid in brain tissue. The estimate accounts for recycling of unlabeled amino acids from tissue protein breakdown by means of a factor (k) that was determined in control and Tsc2 +/À mice. The value of k was higher in Tsc2 +/À mice, indicating that a greater fraction of leucine in the tissue precursor pool for protein synthesis is derived from the plasma compared to controls, consistent with reduced rates of protein degradation. We determined rCPS in freely moving, awake male Tsc2 +/À and control mice, and we used the determined values of k in the calculation of rCPS. Unexpectedly, we found that rCPS were significantly decreased in 16 of the 17 brain regions analyzed in Tsc2 +/À mice compared to controls. Our results indicate a complex role of mTORC1 in the regulation of cerebral protein synthesis that has not been previously recognized.
Tuberous sclerosis complex (TSC) is an autosomal dominant disorder affecting about 1 in 6000 people. It is a multisystemic disorder that causes benign growths throughout the body including the kidney, liver, heart, lungs, and skin. The brain pathology is the most debilitating component of TSC, as patients often experience epilepsy, intellectual disability, and autism spectrum disorders (Northrup and Krueger 2013) . TSC occurs as the result of a mutation in either the TSC1 or TSC2 gene. The protein products of these genes, hamartin and tuberin, respectively, form a complex and act as a GTPase-activating protein on Ras homolog enriched in brain (Rheb); this complex inhibits the downstream mammalian target of rapamycin complex 1 (mTORC1) (Inoki et al. 2003) . Increased activity of mTORC1 has been found in many TSC lesions including tubers. mTORC1 activation leads to subsequent phosphorylation of the 40S ribosomal protein subunit S6 (pS6) and activation of eukaryotic translation initiation factor 4E (eIF4E). These proteins are involved in the regulation of protein synthesis in the cell. eIF4E is involved in directing ribosomes to the mRNAs and is a requirement for almost all mRNA to be translated into protein (Sonenberg et al. 1979) . The current thinking is that up-regulation of these signaling pathways, as in the case of TSC, would result in increased protein synthesis. A dysregulation of protein synthesis could have serious consequences for many brain functions including learning and memory and neural plasticity.
Despite this, results of [ 35 S]methionine/cysteine metabolic labeling studies in hippocampal slices indicate that Tsc2 +/À mice have decreased rates of protein synthesis (Auerbach et al. 2011) . This study raises several important questions. First, hippocampal slices are an ex vivo model; it remains unknown how these results relate to protein synthesis in vivo. Second, it is not known if this pathology is specific to the hippocampus, or if rates of protein synthesis are affected in other brain regions.
We have used the quantitative autoradiographic L-[1-
14 C] leucine method to measure regional rates of cerebral protein synthesis (rCPS) in vivo in adult male Tsc2 +/À and control mice. The use of autoradiography permits the simultaneous determination of protein synthesis rates in all regions of the brain. The study of protein synthesis in vivo allows for measurements to be made under both normal and altered functional and physiological states. The method is based on a compartmental model for the behavior of leucine in the brain. The model takes into account dilution of the precursor amino acid pool by unlabeled amino acids derived from protein degradation. In separate groups of mice, we determined this dilution for leucine and found that in Tsc2 +/À mice compared with controls, a greater fraction of the precursor leucine pool comes from the plasma. We used this in the computation of rCPS in our studies. We measured rCPS in male Tsc2 +/À mice at 3 months of age in 17 brain regions and found that rCPS were significantly decreased in 16 of these brain regions. This indicates that, at least in the brain, the role of mTORC1 in regulation of protein synthesis is more complex than generally thought.
Methods
This study was not pre-registered.
Animals

Tsc2
+/À heterozygous and control breeding pairs on a C57BL/6J 
Surgery
Mice were prepared for rCPS studies by surgical implantation of polyethylene catheters into a femoral artery (PE-10) and vein (PE-8) as described previously (Smith and Kang 2000) . Surgery was performed under light isoflurane anesthesia. Isoflurane was the anesthesia of choice because of its safety, rapid induction and recovery, and our extensive experience with this anesthetic gas in rodent studies. Catheters were threaded sub-dermally along the back and exited at the base of the skull, to prevent mice from biting or pulling on the tubing. Mice recovered overnight in a clear plastic cylindrical cage (13 cm in diameter) with food and water provided ad libitum.
rCPS measurement rCPS was determined as previously described (Smith et al. 1988) . Following overnight recovery from the surgical procedure, the experimental period began in the morning by intravenous injection of 100 lCi/kg L-[1-14 C]leucine (60 mCi/mmol) (Moravek, Inc., Brea, CA, USA) in~30 lL of normal saline. Arterial samples were collected over the 60 min experimental interval to determine the time course of [ 14 C]leucine-specific activity (SA) in plasma as previously described (Smith and Kang 2000) . After 60 min, mice were killed by intravenous injection of Beuthanasia-D (Merck Sharp & Dohme Corp., Kenilworth, NJ, USA) and brains were rapidly removed and frozen on dry ice. Serial 20 lm sections were cut on a CM1850 cryostat (Leica, Deerfield, IL, USA) at À20°C and mounted on gelatin-coated slides (FD Neurotechnologies, Columbia, MD, USA). Slides were fixed in 10% formalin and exposed for 42 days on Super RXN film (Fuji Film Corp., Tokyo, Japan) along with [ 14 C]methylmethacrylate standards previously calibrated against similarly treated brain tissue sections as previously described (Smith and Kang 2000) . Autoradiograms were digitized with a 12-bit QImaging digital camera (QImaging, Surrey, BC, Canada) with a pixel size of 11 lm and analyzed with an MCID Elite image processing system (Interfocus Imaging Ltd, Linton, Cambridge, UK) (RRID: SCR_014419). Regions of interest (ROIs) were identified by referencing a mouse brain atlas (Franklin and Paxinos 2001) .
The concentration of [ 14 C]leucine in each ROI was determined by comparing the optical density of the ROI to the 14 C concentration curve determined by the calibrated standards. rCPS was computed as previously described by the operational equation of the method (Smith et al. 1988) :
in which R i is the rate of leucine incorporation into protein in tissue (i). P i *(T) is the concentration of 14 C in tissue (i) at any time, T, after injection of the tracer into the circulation. k i is the fraction of leucine in the precursor pool for protein synthesis in tissue (i) that is derived from the plasma. The remainder (1-k i ) comes from proteolysis in the tissue. k i was evaluated in separate groups of animals. C p *(t) and C p are the concentrations of labeled and unlabeled leucine in the plasma, respectively, and t is the variable time. Two Tsc2 +/À mice were excluded from the study because their rCPS values were statistical outliers (greater than two standard deviations from the mean).
Determination of k i k i for the whole brain (k WB ) was evaluated in separate groups of animals as previously described (Smith et al. 1988) . Experimentally, k WB is the steady-state ratio of the SA in the brain tRNAbound pool to that of the arterial plasma. We used a programmed intravenous infusion of L- [4, H]leucine (60-120 Ci/mmol) (Moravek, Inc.) designed to achieve and maintain a constant arterial plasma [ At the end of the infusion, mice were decapitated, and brains were rapidly removed and cooled in ice-cold 0.25 M sucrose, weighed, and homogenized in 5 mL of 0.25 M sucrose containing 10 mM vanadyl ribonucleoside complex to inhibit ribonuclease, 6 mg of uncharged tRNA as carrier, and 0.02 mM L-norleucine as an internal standard. Homogenates were centrifuged at 100 000 g for 1 h at 4°C, and the tRNA-bound amino acids were purified as described previously (Smith et al. 1988) . The pure tRNA fraction was dissolved in 50 mM sodium carbonate (pH 10) to deacylate the aminoacyl-tRNA. The free amino acids previously bound by tRNA were separated by precipitating tRNA in ethanol followed by centrifugation at 12 000 g for 20 min. The supernatant fraction was then dried under a stream of N 2 and redissolved in 40 lL of 0.2 M sodium citrate (pH 2.2).
The tissue free amino acid fraction, and the deproteinized plasma samples were assayed for leucine concentration by means of HPLC with post-column derivatization with ο-phthaldehyde and fluorometric detection. Column eluates were collected every 30 s and assayed for 3 H with a Packard Liquid Scintillation Counter model 2250CA (PerkinElmer Life Sciences, Branford, CT, USA). SA was calculated from the total 3 H in all fractions in the leucine peak and the total measured leucine content in the peak.
k WB was calculated as the ratio of the steady-state SA of leucine in the tissue tRNA-bound pool to that of the free leucine in the arterial plasma. Only animals with relatively constant plasma leucine-specific activities (coefficients of variation < 10%) were included in the analysis. Four animals (two control and two Tsc2 +/À ) were omitted because arterial plasma SAs were steadily and significantly rising, and one Tsc2 +/À animal was omitted because arterial plasma leucine concentrations were >300 nmol/mL (significantly higher than the normal range). Two animals (one control and one Tsc2 +/À ) were not included in the calculation of k WB because the leucine concentrations in the tRNA-bound fraction were too low (< 9 pmol) to reliably quantify likely because of losses during the purification procedure.
Western blot analysis
Mice were rapidly decapitated and brains rapidly dissected. The hippocampus was placed into a Precellys soft tissue homogenizing tube with ceramic beads (Bertin Corporation, Rockville, MD, USA) and a 5% (weight/volume) solution of T-Per protein extraction reagent (Thermo-Scientific, Waltham, MA, USA) with 1% EDTA (Thermo-Scientific) and 1% Halt Protease and Phosphatase Inhibitor Cocktail (Thermo-Scientific). The tissue was homogenized two times for 30 s at 2000 9 g. The homogenate was centrifuged at 15 000 g for 15 min at 4°C, the supernatant collected, and the protein concentration measured by means of a bicinchoninic acid protein assay (Thermo-Scientific). For normalization of western blots, we employed the Stain-Free technology (Bio-Rad Laboratories, Hercules, CA, USA). Protein (10 lg) was denatured at 95°C for 5 min (or 70°C for 10 min for tuberin) with an equal volume of Laemmli buffer (Mixed with 2-mercaptoethanol 1 : 20), and electrophoresed on a 4-15% Mini-PROTEIN TGX Stain-Free gel (Bio-Rad Laboratories) and transferred to a nitrocellulose membrane (Bio-Rad Laboratories). The membrane was incubated overnight at 4°C in the primary antibody solution followed by 1 h at 21°C in secondary antibody [goat antirabbit horseradish peroxidase-linked 1 : 10 000 (Bio-Rad Laboratories)]. Antibody staining was visualized after incubation in Clarity substrate (Bio-Rad Laboratories) on a ChemiDoc MP Imager (BioRad Laboratories) and analyzed using Image Lab Software (Bio-Rad Laboratories) (RRID: SCR_014210). Primary antibodies (Cell Signaling, Danvers, MA, USA) were: Tuberin (4308) (RRID: AB_10547134), pmTOR (5536) (RRID: AB_10691552), mTOR (2983) (RRID: AB_2105622), p-p70 S6K (9234) (RRID: AB_2269803), p70 S6K (2708) (RRID: AB_390722), pS6 235/ 236 (2211) (RRID: AB_331679), pS6 240/244 (2215) (RRID: AB_331682), S6 (2217) (RRID: AB_331355), p4EBP1 (2855) (RRID: AB_560835), and 4EBP1 (9644) (RRID: AB_2097841), pAKT S473 (4060) (RRID: AB_2315049), pAKT Thr308 (4056) (RRID: AB 331163), AKT (9272) (RRID: AB_329827), pAMPK (2535) (RRID: AB_331250), and AMPK (5832) (RRID: AB_10624867). All antibodies were diluted 1:1000.
Statistical analysis
The number of animals to be studied for the rCPS experiments was determined by power analysis based on our published data in Fmr1 KO mice in which we observed a 8-10% coefficient of variation and a genotype difference of 8-25%. We hypothesized a similar effect size and variability in the Tsc2 +/À mice. On the basis of data and a difference between the two groups of 12%, we estimated that we could detect changes in rCPS at the p ≤ 0.05 level with a statistical power of 85% with 10/group. 
Results
Steady-state experiments
To correct for possible differences in the recycling of leucine between control and Tsc2 +/À animals, we determined k WB (the fraction of unlabeled leucine in the precursor pool derived from arterial plasma). In the same experiments, we also determined the ratio of steady-state SAs in the free amino acid pool in the tissue and the arterial plasma. A typical experiment is shown in Fig. 1 . The five Tsc2 +/À and six control mice matched for age and body weight were studied while awake and freely moving under normal physiological conditions (Table 1) . Mean values of k WB (ratios of steady-state SA in the tRNA-bound pool to plasma) were statistically significantly higher in Tsc2 +/À mice (p = 0.035; Student's t-test) ( Table 2 ). This indicates that, for control mice, 59% of leucine in the precursor pool comes from plasma and 41% comes from the breakdown of protein in the tissue, whereas in Tsc2 +/À animals, the fraction of leucine in the precursor pool from plasma is 73%, and the fraction of leucine derived from protein breakdown is 27%. The fraction of leucine in the free (acid-soluble) amino acid pool in brain originating from arterial plasma was similar in both genotypes.
Regional rates of cerebral protein synthesis
We measured rCPS in adult male Tsc2 +/À and control mice well matched for age and body weight and studied awake and animal. Arterial plasma shows a relatively constant SA over the 120 min study and particularly between 60 and 120 min. The free acidsoluble leucine SA in the brain at 120 min relative to the plasma is similar for both genotypes. In contrast, the tRNA-bound leucine SA is closer to that of the plasma in the Tsc2 +/À mouse compared to the control indicating a higher value of k WB in the Tsc2 +/À mouse. Values are the means AE SEM for the number of mice indicated in parentheses. Physiological variables (except for brain weight) were determined at the outset of the study. (Table 3) . Values of rCPS were computed with the value for k WB corresponding to the genotype.
We determined rCPS in 17 regions of brain (Table 4 ). In 16 of the brain regions, mean rCPS was statistically significantly reduced in Tsc2 +/À (mice n = 9) relative to controls (n = 10) with differences ranging between 21% and 31%. The regions include four areas of the cortex (frontal, parietal, auditory, and visual), two areas of the corpus callosum (medial and lateral), two areas of the thalamus (dorsomedial and ventral posterior), two hypothalamic nuclei (paraventricular nucleus and supraoptic nucleus), the basolateral amygdala, two areas of the hippocampus (dorsal and ventral), and the median raphe. Within the dorsal hippocampus, we also analyzed the pyramidal cell layer of CA1, a cell body-rich area, and the stratum radiatum, a synapse-rich area. In the cerebellum differences in rCPS did not reach statistical significance. Representative images (Figs 2 and 3) illustrate that the effects are widespread.
In effort to determine if rCPS might be different in postmitotic versus actively dividing neurons (areas of adult neurogenesis), we did a post hoc evaluation of the dentate gyrus and subventricular zone. rCPS were statistically significantly lower in Tsc2 +/À mice compared to controls in both regions (Table 5) .
Western blot analysis
We confirmed the phenotype of adult Tsc2 +/À mice by probing relative levels of tuberin in the hippocampus by means of western blots (Fig. 4a) . Our analysis indicates that relative tuberin levels were reduced by 25% in Tsc2 +/À mice (p = 0.01, Student's t-test) (Fig. 4b) . A reduction in tuberin would be expected to reduce the inhibition of mTORC1 by the tuberin/hamartin complex and consequently up-regulate the mTORC1 pathway. We probed for p-mTOR and found that mean values were slightly higher in Tsc2 +/À mice but the difference was not statistically significant (p = 0.127). In accord with this, we also probed for downstream effectors of mTORC1, p-p70S6K, p-S6 235/236, p-S6 240/244, p-4E-BP1, p-AKT S473, p-AKT Thr308, and pAMPK, and found no statistically significant effects. Moreover, mean values did not show any consistent trends (Fig. 4) . The results of these analyses suggest that the mTORC1 pathway is not activated in hippocampus of adult Tsc2 +/À mice.
Discussion
This study is, to our knowledge, the first study of brain protein synthesis in vivo in this genetic mouse model of TSC. Results of our study indicate that in Tsc2 +/À mice, despite a demonstrated reduction in levels of tuberin (TSC2), protein synthesis rates in brain are substantially reduced. This unexpected finding is in accord with our further finding of a lack of an increased activity in the mTORC1 pathway in this mouse model. Our report suggests that there may be Values are the means AE SEM for the number of mice indicated in parentheses. The arterial plasma leucine concentration is the mean of the time-weighted averages over the 60 min study. All other variables were determined at the outset of the study. . Data were analyzed by means of repeated measures ANOVA with region as within subject factor and genotype as the between subject factor. The region 9 genotype interaction was statistically significant (F 3.26,72 .62 = 9.098, p < 0.001). Region-specific differences between genotypes were assessed by means of post hoc pairwise comparisons (Bonferroni correction for multiple comparison ttests).
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To measure rCPS in control and Tsc2 +/À mice, we used the autoradiographic L-[1-14 C]leucine method based on a compartmental model of the behavior of leucine in brain. The method is comprehensive in that it estimates the time course of SA of the tracer in the tissue and corrects for dilution of the precursor pool SA by amino acids derived from breakdown of unlabeled protein in the tissue. This correction is by means of a factor, k WB , in the equation (Eq 1) that is determined in a separate group of animals. In our initial estimates of rCPS, we assumed that k WB did not change in Tsc2 +/À mice, and in our computations, we used the value determined previously in control and Fmr1 knockout (KO) mice (Qin et al. 2005) for both groups of animals. Comparison of our results in control and Tsc2 +/À mice calculated with this assumption of a constant value of k indicated that rCPS were decreased in selective regions of the brain in the Tsc2 +/À mice. We reconsidered our assumption of an unchanged value of k WB . If the value of k WB was decreased in the Tsc2 +/À mice, we would have underestimated rCPS. Therefore, we evaluated k WB in the two groups of animals. The value determined in control mice (0.59) was very similar to our previous result in control and Fmr1 KO mice of 0.60 (Qin et al. 2005) . In the Tsc2 +/À mice, the value of k WB was unexpectedly increased, not decreased. Because k WB is in the denominator of the equation for rCPS (Eq 1), the underestimation of k WB meant that we had overestimated rCPS. Rates of protein synthesis calculated with the genotype- appropriate values of k WB were further decreased in Tsc2 +/À mice compared to controls. A change in the value of k WB also has implications for our understanding of the process of protein degradation in the brain. There are two sources of the essential amino acid, leucine, in the brain: the plasma and tissue protein degradation. By definition, k is the fraction of the precursor pool derived from the plasma, the remainder, 1Àk, comes from tissue protein breakdown. In Tsc2 +/À mice, the value of k WB is increased indicating that the contribution of leucine in the precursor pool that comes from tissue protein degradation is lower than in controls. From this we can infer that the rate of protein degradation may also be reduced. Decreases in both rates of protein degradation and synthesis in the Tsc2 +/À mice is consistent with the finding that the brain size is unaffected and implies that the steady-state turnover of protein is decreased. Decreased protein synthesis could have important implications for neural plasticity in Tsc2 +/À mice and may be responsible for the behavioral impairments and learning and memory deficits seen in this model (Ehninger et al. 2008) . Interestingly, in a mouse model of fragile X syndrome, increased protein synthesis can lead to many similar behavioral phenotypes including learning and memory impairments (Auerbach et al. 2011) . This suggests that dysregulation of protein synthesis, in either direction, results in behavioral abnormalities.
Many previous studies have addressed changes in translation indirectly by measuring relative levels of signaling molecules involved in translation regulation. This approach gives us insight into some cellular processes, but does not address the process of translation per se. A change in a signaling molecule may be counteracted by other regulatory pathways and does not necessarily indicate a change in the process regulated. For example, autophagy, blocked by mTORC1 activation in dividing cells, is enhanced in Tsc2 +/À neurons via AMPK activation (Kondratov et al. 2006) . Another approach taken to assess translation is by measuring levels of specific protein targets, but a change in a specific protein target could be because of a change in either its synthesis or its degradation. Studies of incorporation rates of a labeled amino acid into protein in cell lines and in vitro preparations also must be interpreted with caution as they do not necessarily reflect the conditions in the tissue in vivo.
In one study of an ex vivo preparation of hippocampal slices from Tsc2 +/À mice, a small but consistent decrease in [ 35 S]methionine/cysteine incorporation into protein was reported (Auerbach et al. 2011) . This decrease was accompanied by a decrease in mGluR-stimulated LTD, and both abnormalities were restored by acute treatment with rapamycin. These results suggested that in the hippocampal slice, up-regulated mTORC1 activity was pathogenic. Our results on rates of protein synthesis are in accord with this ex vivo study, but our analysis of the signaling pathways do not support enhanced activity of the mTORC1 pathway in the hippocampus. mTORC1 is part of the larger PI3K/AKT insulin signaling pathway which is regulated by an intricate set of feedback mechanisms (Huang and Manning 2009) . A second mTOR complex (mTORC2), is also affected by the TSC1/TSC2 complex which is less well understood. Studies have shown that complete activation of mTORC2 requires the TSC1/ TSC2 complex (Huang et al. 2008) . In addition, the downstream product of mTORC1, S6K, can form a feedback loop and inhibit mTORC2 (Liu et al. 2012) . Therefore, loss of Tsc2 may result in reduced mTORC2 activation, both via a direct and an indirect mechanism. We used western blotting to measure p-AKT at Ser473 as a surrogate for mTORC2 activity in hippocampal lysates from six control and six Tsc2 +/À mice. Our results suggest a decrease in mTORC2 activity in Tsc2 +/À mice, but differences were not statistically significant (p=0.15).
Protein synthesis may also be reduced because of AMPactivated protein kinase (AMPK) which can inhibit mTORC1 independent of its activity on Tsc2 (Sun et al. 1995) . AMPK is activated by cellular stresses that reduce ATP (metabolic poisoning, oxidative stress, hypoxia, or nutrient deprivation) (He et al. 2014) . Oxidative stress has been shown previously in mouse models of Tsc2 deletion (Di Nardo et al. 2009; Reith et al. 2011) . In addition, AMPK has been shown to inhibit protein synthesis via an mTOR-independent mechanism (Crowell et al. 2015) . Neuronal knockdown of Tsc2 has been shown to result in up-regulation of AMPK (Kondratov et al. 2006) , suggesting that loss of Tsc2 may result in up-regulation of cellular stress, up-regulation of AMPK, and a subsequent decrease in protein synthesis. Through western blotting, we detected slightly higher levels of p-AMPK in the hippocampus from Tsc2 +/À mice, but genotype differences were not statistically significant. Future studies will address the involvement of mTORC2 and AMPK in regulation of protein synthesis in TSC.
In spite of significantly decreased levels of tuberin in the hippocampus in Tsc2 +/À mice compared to controls, mTORC1 activity was unchanged, and rCPS were decreased. These results suggest that in the brain with a reduction in Tsc2, a compensatory feedback loop is overactivated resulting in decreased rates of cerebral protein synthesis. These results have significance for our understanding the brain manifestation of TSC and for the development of mechanism-based treatment strategies for this disease.
